
Principal Investigator
Jae Hun Shin
Ph.D.
Associate Professor, Bio-Convergence
Integrated Science & Engineering Division, Yonsei University
Assistant Professor Adjunct, Internal Medicine (Endocrinology), Yale University
Biography
Dr. Jae Hun Shin is an Associate Professor in the Integrated Science & Engineering Division at Yonsei University, where he leads the Tumor Immunology Lab. He also serves as an Adjunct Assistant Professor in the Section of Endocrinology, Internal Medicine at Yale University.
Dr. Shin received his Ph.D. in Immunobiology from Yale University and subsequently completed postdoctoral training there. His research focuses on a process called trogocytosis — the transfer of membrane fragments between cells — and how cancer cells exploit this mechanism to acquire immune regulatory molecules from T cells, thereby evading anti-tumor immunity.
His laboratory employs a multidisciplinary approach combining mass spectrometry, RNA sequencing, CRISPR/Cas9 screening, organoid models, and in vivo systems to identify immunotherapeutic targets and develop novel cancer immunotherapies including mRNA-LNP and CAR-T cell strategies.
Education
Ph.D. in Immunobiology
Yale University
2014
M.S. in Biotechnology
Yonsei University
2007
B.S. in Biotechnology
Yonsei University
2005
Positions
Associate Professor
Bio-Convergence, Integrated Science & Engineering Division, Yonsei University
2019 - Present
Assistant Professor Adjunct
Section of Endocrinology, Internal Medicine, Yale University
Current
Postdoctoral Associate
Yale University
2014 - 2019
Research Associate
National Cancer Center, Korea
2007 - 2009
Research Focus
Trogocytosis in Cancer Immune Evasion
Investigating how cancer cells acquire immune regulatory molecules from T cells via trogocytosis to evade anti-tumor immunity.
Immunotherapeutic Target Identification
Identifying novel targets for immunotherapy in metastatic cancers using mass spectrometry, RNA-seq, and CRISPR/Cas9 screening.
Therapeutic Development
Developing next-generation cancer immunotherapies including mRNA-LNP and in vivo CAR-T approaches.